

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

Information for the public

Published: 18 August 2021

www.nice.org.uk

Abiraterone (Zytiga) with prednisone or prednisolone plus androgen deprivation therapy (ADT) is not normally available on the NHS for treating newly diagnosed, high-risk, hormone-sensitive, metastatic prostate cancer in adults. Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Prostate Cancer UK](#), 0800 074 8383
- [Tackle Prostate Cancer](#), 0800 035 5302
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 00 00

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4224-4